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Background: Preeclampsia is a significant cause of maternal and fetal mortality and morbidity worldwide. We
previously reported associations between trichothiodystrophy (TTD) nucleotide excision repair (NER) and
transcription gene mutations in the fetus and the risk of gestational complications including preeclampsia. TTD
NER/transcription genes, XPD, XPB and TTD-A, code for subunits of Transcription Factor (TF)IIH. Interpreting XPD
mutations in the context of available biochemical data led us to propose adverse effects on CDK-activating kinase
(CAK) subunit of TFIIH and TFIIH-mediated functions as a relevant mechanism in preeclampsia. In order to gain
deeper insight into the underlying biologic mechanisms involving TFIIH-mediated functions in placenta, we
analyzed NER/transcription and global gene expression profiles of normal and preeclamptic placentas and studied
gene regulatory networks.
Results: We found high expression of TTD NER/transcription genes in normal human placenta, above the mean of
their expression in all organs. XPD and XPB were consistently expressed from 14 to 40 weeks gestation while
expression of TTD-A was strongly negatively correlated (r = -0.7, P < 0.0001) with gestational age. Analysis of gene
expression patterns of placentas from a case-control study of preeclampsia using Algorithm for Reconstruction of
Accurate Cellular Networks (ARACNE) revealed GTF2E1, a component of TFIIE which modulates TFIIH, among major
regulators of differentially-expressed genes in preeclampsia. The basal transcription pathway was among the largest
dysregulated protein-protein interaction networks in this preeclampsia dataset. Within the basal transcription
pathway, significantly down-regulated genes besides GTF2E1 included those coding for the CAK complex of TFIIH,
namely CDK7, CCNH, and MNAT1. Analysis of other relevant gene expression and gene regulatory network data also
underscored the involvement of transcription pathways and identified JUNB and JUND (components of transcription
factor AP-1) as transcription regulators of the network involving the TTD genes, GTF2E1, and selected gene regulators
implicated in preeclampsia.
Conclusions: Our results indicate that TTD NER/transcription genes are expressed in placenta during gestational
periods critical to preeclampsia development. Our overall findings suggest that impairment of TFIIH-mediated function
in transcription in placenta is a likely mechanism leading to preeclampsia and provide etiologic clues which may be
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Preeclampsia is a complex disorder affecting about 7%
of all pregnancies and a major cause of severe intrauter-
ine growth restriction (IUGR) and preterm birth [1].
Preeclampsia has the potential to develop into severe
preeclampsia and hemolysis, elevated liver enzymes and
low platelets (HELLP) syndrome posing risks of fatality
for both mother and infant [2]. While the exact biologic
mechanisms leading to preeclampsia remain elusive, ab-
normal placentation associated with shallow trophoblast
invasion and inadequate remodeling of maternal uterine
spiral arteries [3,4] followed by placental hypoxia [5] and
oxidative stress [6,7], caused by compromised blood flow
into the placenta, have been implicated in the underlying
pathology of this condition. The intricacies of the in-
volvement of transcription and repair mechanisms in
this process have not been elucidated.
We first conceived the hypothesis for the association
between nucleotide excision repair (NER) and transcription
gene abnormalities in the fetal genome and risk of gesta-
tional complications in 2003 based on our clinical observa-
tions and systematic genetic epidemiologic investigations in
families with trichothiodystrophy (TTD) [8]. TTD is a rare
(affected frequency of 1 in 106) recessive disorder [9] caused
by mutations in XPD (ERCC2), XPB (ERCC3), and TTD-A
(GTF2H5), which encode three of the subunits of transcrip-
tion factor (TF)IIH, as well as in TTDN1 [9-11]. Mutations
in XPB and XPD can cause other rare recessive DNA repair
disorders such as xeroderma pigmentosum (XP) [9,12].
TFIIH is a multifunction general transcription factor
with roles in both basal and activated transcription as
well as in DNA repair. TFIIH is a complex consisting
of ten proteins and two domains, a CDK-activating kinase
(CAK) domain and a core domain [13]. TFIIH is a compo-
nent of the RNA Polymerase (Pol)II-mediated transcription
machinery [14,15]. Both domains of TFIIH and its inter-
action with TFIIE are needed for its function in tran-
scription initiation and RNA Pol-II elongation [16]. For
its function in the nucleotide excision repair pathway,
TFIIH’s core domain alone and its helicase activity via
XPD and XPB are needed [17].
Our recent study of XP and TTD suggested a link
between TTD- but not XP-associated XPD mutations
in the fetus and risk of placental maldevelopment and
preeclampsia [18]. This study [18] and our subsequent
integrative transcriptome analysis [19] implicated impair-
ment of TFIIH-mediated functions in placenta as a possible
mechanism involved in preeclampsia. Our meta-analysis
of preeclampsia case-control studies suggested that a large
number of preeclampsia-specific genes were directly
induced by hypoxia and highlighted the signature of oxi-
dative stress in preeclamptic placentas [19]. Given that
NER is involved in oxidative damage repair [20], a critical
question to resolve would be whether impairment of theNER function of TFIIH could also be relevant to the
mechanism leading to preeclampsia.
Our current study focuses on deciphering whether
TFIIH’s transcription function alone or a combination of its
transcription and repair functions in placenta is relevant
to the development of preeclampsia. In order to resolve
this question and gain deeper insight into the biologic
mechanisms which underlie the association between NER/
transcription gene abnormalities in the fetus, impairment
of TFIIH-mediated functions in placenta, and preeclampsia,
we conducted analyses of several relevant gene expression
and gene regulatory network datasets.
Results
Analysis of NER/transcription gene profiles in normal
human placenta
We analyzed the relative expression of TTD NER/
transcription genes in placenta compared to other normal
human tissue including skin in GSE96 [21], given that skin
abnormalities are among the most prominent features of
TTD suggesting high expression of TTD NER/transcription
genes in skin. Statistically-significant higher expres-
sion was observed for TTD-A [False Discovery Rate
(FDR) = 0.03, Fold Change = 3.5)] and XPB (FDR = 0.06,
Fold Change = 5.9) in placenta compared to skin and other
tissues. XPD expression was also higher in placenta than
skin and most other tissues but the difference did not reach
statistical significance (Additional file 1: Figure S1a).
Preeclampsia is identified clinically as hypertension that
first occurs after 20 weeks gestation [1] but may be due to
processes which develop earlier, therefore, genes relevant
to preeclampsia would be expected to be expressed during
the critical gestational periods of ≤20 weeks gestation as
well. In order to infer the relevance of the TTD NER/
transcription genes to processes which lead to preeclampsia,
we conducted time-course analysis of the three TTD NER/
transcription gene expression patterns in normal placenta
from 14-40 weeks gestation in GSE5999 [22]. We found
high expression of all TTD NER/transcription genes in hu-
man placenta from first to third trimester. While XPD and
XPB were consistently expressed from 14 to 40 weeks gesta-
tion, expression of TTD-A was strongly negatively correlated
(r = -0.70, P < 0.0001) with gestational age (Additional file 1:
Figure S1b). These results indicate that TTD NER/
transcription genes are expressed in placenta at early
gestation and during gestational periods which are critical
for preeclampsia development.
Placental gene expression profiles in a preeclampsia
case-control study
In order to reconstruct gene regulatory networks of pre-
eclamptic placentas, we analyzed global gene expression
profiles of placenta from a large preeclampsia case-
control study dataset (GSE 10588) [23]. In our previous
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had used gene annotation pathway-based approaches such
as gene ontology (GO) [24] to infer regulatory relationships.
In our current study, however, we used Algorithm for
Reconstruction of Accurate Cellular Networks (ARACNE)
[25], a robust information-theory based method specifically
developed to reconstruct mammalian cellular gene regula-
tory networks using gene expression profiles. Annotation-
based methods such as GO are limited to previously known
relationships, whereas computational-based methods such
as ARACNE are more suited for identification of new
gene associations and network reconstruction. ARACNE
has been shown to outperform several correlation and
probabilistic (Bayesian)-based network reconstruction
methods [26]. To our knowledge, ARACNE has never
been applied to reconstruction of gene networks of pre-
eclamptic placentas.
Application of ARACNE to global gene expression
profiles of placenta from the largest available preeclamp-
sia case-control dataset fitting our selection criteria
(GSE 10588) [23] revealed 2000 genes (i.e., nodes) found
to be significant based on their interactions with other
genes in the network and 22000 significant interactions
(i.e., edges) between the identified genes (Figure 1a).
The interconnectivity analysis depicted in Figure 1a
points at the complexity of the altered gene regulatory
networks of preeclamptic placentas and at GTF2E1, which
codes for a component of TFIIE, as the most intercon-
nected gene in the network (Figure 1a).
In ARACNE analysis, the most interconnected gene(s)
are inferred to be the master regulator(s) in the network
defined as gene(s) with the highest number of significant
interactions with other genes within the network. In our
analysis, the top gene in the network in terms of the
largest number of interactions was GTF2E1 with 120
significant interactions (Figure 1b). Pathway analysis of
GTF2E1-regulated genes (Figure 1c) revealed the most
prominent canonical pathways as those related to tran-
scription and translation such as nutrient uptake, energy
metabolism and protein degradation pathways (Figure 1d).
The basal transcription pathway was among the largest
dysregulated protein-protein interaction networks in this
preeclampsia dataset (Figure 1e). Within the basal tran-
scription pathway, the significantly downregulated genes
included GTF2E1 (FDR = 8.72*10−7, Fold Change = 1.7)
and those coding for all three components of the CAK
complex of TFIIH, namely CCNH (FDR = 1.14*10−5, Fold
Change = 1.7), CDK7 (FDR = 0.0088, Fold Change = 1.3)
and MNAT1 (which codes for MAT1) (FDR = 7.92*10−5,
Fold Change = 1.3) (Figure 1e). CAK complex of TFIIH is
needed for its transcription function, therefore, downregu-
lation of GTF2E1 and all three subunits of the CAK do-
main of TFIIH in preeclamptic placentas points towards
impairment of TFIIH’s role in transcription.Transcriptome analysis of human umbilical vein
endothelial cells
In order to validate the finding of GTF2E1 as the regulator
of the gene network altered in preeclampsia, we analyzed
the Human Umbilical Vein Endothelial Cells (HUVEC)
transcriptome dataset (GSE27871) [27] to compare the
affected gene regulatory networks of GTF2E1 and FLT1
siRNA-inhibited umbilical cord endothelial cells. FLT1
had been identified as a molecular mediator of clinical
symptoms of preeclampsia in previous studies [5]. Our
analysis of HUVEC dataset identified similarity (p < 10−6)
between GTF2E1 and FLT1 siRNA datasets suggesting
similar consequences for inhibition of FLT1 tyrosine pro-
tein kinase and inhibition of transcription in the endothe-
lial cells (Figure 2a and b). Network reconstruction using
correlation coefficients (FDR < 0.01) revealed clustering of
FLTs with proteins involved in RNA Pol-II holoenzyme,
such as general transcription factors (GTFs) and histone
deacetylases (HDAC), underscoring the relevance of tran-
scription network (Figure 2c).
Analysis of relevant datasets to identify common
regulatory networks of genes implicated in preeclampsia
We analyzed the reactome database [28] to identify pro-
teins with direct and indirect (up to secondary) interactions
with GTF2E1 and XPD in order to gain clues as to the cel-
lular processes marking their involvement in preeclampsia.
This analysis revealed direct interaction between GTF2E1
and ERCC2 (XPD), both of which belong to a highly
interactive protein cluster network (Figure 3). In the
reactome database, XPD was found to have direct and
indirect interactions with proteins involved in several
cellular processes including transcription, DNA repair and
cell cycle (Figure 3). GTF2E1 was found to interact with
proteins involved in transcription. The ERCC2-GTF2E1
connection and its extended (up to secondary interaction)
protein interaction network highlighted XPD’s involvement
in transcription (depicted in the left side of Figure 3) versus
its role in other cellular functions such as repair and cell
cycle (depicted in the right side of Figure 3), with respect to
the mechanism leading to preeclampsia (Figure 3).
We also conducted an analysis of ENCODE Chip Seq
data [29] to infer common transcription regulatory net-
works of selected genes (such as TTD genes and GTF2E1)
and gene regulators (such as EGFR [19], ATF3 [19], and
FLT1 [5]) implicated in preeclampsia. This analysis
revealed a common transcription regulatory network
involving EGFR, ATF3, FLT1, GTF2E1 and TTD genes
(i.e., XPD, XPB, TTD-A and TTDN1) (Figure 4). These
analyses revealed regulation of GTF2E1 by ATF3 and
common regulation of XPD and GTF2E1 by TBP (TATA
box binding protein), a crucial transcription initiation factor
and a subunit of TFIID. JUNB and JUND, components
of the AP-1 transcription factor involved in cellular
Figure 1 Placental gene expression profiles in a preeclampsia case-control study (GSE10588) [23]. Panel a. Network of significant
connections (edges) between the genes (nodes). Size of each node (representing an expressed gene) is proportional to the number of
interactions with other genes and is, therefore, directly proportional to the number of significant associations found. Panel b. Bar graph of the
number of connections for the most interconnected genes in the network predicted by ARACNE. GTF2E1 was identified as the gene with the
largest number of interactions/connections in the network. Panel c. Subnetwork of GFT2E1-regulated genes. Panel d. Canonical pathway analysis
of GTF2E1-regulated genes. Panel e: Cytoscape visualization of dysregulated protein-protein interaction networks. Green nodes signify downregulation
and red nodes upregulation of each gene product.
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Figure 2 Analysis of a human umbilical vein endothelial cells dataset (GSE 27871) [27] created using siRNA-mediated knockdown of
400 specific signaling molecules and transcription factors. Panel a. Pearson correlation analysis of FLT1 siRNA-mediated knockdown with
other datasets revealing a common gene regulatory network of GTF2E1 and FLT1. Panel b. Pearson correlation analysis of GTF2E1 siRNA-mediated
knockdown with other datasets revealing a common gene regulatory network of GTF2E1 and FLT1. Panel c. Correlation matrix of all siRNA-mediated
knockdowns revealing significant (r > 0.95) gene clusters. The gene cluster connecting GTF2E1 and FLT1 (i.e., GTF-FLT-HDA-HSF gene cluster)
is shown in green.
Figure 3 Network of GTF2E1 interacting proteins. Network of interacting proteins with up to second-degree connection to GTF2E1 based on
data from the reactome dataset [28]. Of note, GTF2E1 has a direct interaction with ERCC2 (XPD). Below the Figure is a graphical summary interpretation
depicting the three cellular pathways representing the majority of protein networks with first or second-degree connection to ERCC2 (i.e., Transcription,
Cell Cycle, DNA Repair). The GTF2E1-ERCC2 connection highlights the transcription process (depicted in the left side of the figure).
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Figure 4 Analysis of raw ENCODE Chip Seq regulatory
network data. Transcription factors connecting selected genes
(such as TTD genes and GTF2E1) and gene regulators (such as EGFR,
ATF3, and FLT1) implicated in preeclampsia. Grey circles depict genes
with Chip Seq information in the ENCODE dataset. Open circles depict
genes of interest. JUNB and JUND identified as transcription regulators
of all selected factors within the network.
Moslehi et al. BMC Genomics 2014, 15:373 Page 6 of 11
http://www.biomedcentral.com/1471-2164/15/373proliferation, migration, differentiation and apoptosis [30],
were identified as regulators connecting all genes of interest
implicated in preeclampsia (Figure 4), highlighting the
relevance of transcription pathways to preeclampsia.Discussion
Although singular observations of certain pregnancy
complications were noted in individual case reports of
TTD patients (as illustrated in our recent genetic epide-
miologic study [18]), gestational complications were not
recognized as part of the spectrum of TTD multisystem
disorder until the initiation of our systematic investigations
of the adverse effects of NER/transcription gene abnor-
malities on fetal development in 2003, as described in the
text and authors’ contributions of our previous publi-
cation [8]. Our findings have consistently highlighted
the relevance of the fetal genotype and the exact genetic
abnormality to the mechanism leading to gestational com-
plications such as preeclampsia [8,18].
Based on eight TTD [8,31,32]a and three XP [33-35]a
cases with reported XPD mutations and explicit informa-
tion on presence or absence of preeclampsia (many case
reports and review articles on XP and TTD lacked explicit
information on presence or absence of preeclampsia),
we localized the preeclampsia-associated mutations to
a C-terminal motif and the helicase surfaces of XPD.
Interpreting the XPD mutations in the context of available
biochemical and epidemiologic data led us to propose that
specific subset of XPD mutations in the fetus, associ-
ated with TTD but not XP, may result in higher risk of
preeclampsia due to their adverse effects on binding ofXPD with the CAK and p44 subunits of TFIIH, leading
to impairment of TFIIH-mediated functions in placenta
[18]. As noted in our report [18], a plausible hypothesis
based on data analyzed in our study is that impairment
of transcription-related functions of TFIIH may be relevant
to preeclampsia. Our subsequent integrative transcriptome
analysis shed further light on the link between impairment
of TFIIH-mediated functions in placenta and induction
of molecular mediators of clinical symptoms of preeclamp-
sia through dysregulation of EGFR- and ATF3-dependent
pathways [19].
Our current analyses of gene expression patterns from
several data sources relevant to placenta and preeclampsia
provided additional mechanistic information. We found
high expression of TTD NER/transcription genes in
normal placenta, above the mean of their expression in
all organs including skin where these genes are known
to play an important function. Temporal analysis re-
vealed expression of XPD, XPB and TTD-A in placenta
throughout second and third trimesters and during
critical gestational periods for preeclampsia development.
Interestingly, while XPD and XPB were consistently
expressed in placenta from 14 to 40 weeks gestation,
expression of TTD-A was negatively correlated with ges-
tational age. Preeclampsia was not noted among mothers
of patients with mutations in TTD-A in our initial genetic
epidemiologic study [8,36]. It is unclear how this observa-
tion relates to the unique pattern of expression of TTD-A
in placenta, however, it is plausible that the temporal
expression patterns of these genes could provide clues
into the genotype-phenotype correlations with respect
to gestational complications.
Application of ARACNE to the placental gene expression
profiles of the largest available case-control study of
preeclampsia fitting our selection criteria (i.e., tissue biopsy
from fetal cell-derived histologic subsection of placenta)
revealed GTF2E1 (component of TFIIE which modulates
TFIIH) among major regulators of differentially-expressed
genes in preeclampsia. This finding implicated impaired
TFIIE-TFIIH interaction as a relevant mechanism leading
to preeclampsia. TFIIH and TFIIE are necessary for
accurate transcription; these molecules are believed to
mediate the unwinding of DNA as well as melting of
DNA to allow RNA Pol-II movement [37]. Our findings
in HUVEC suggested the same downstream effects on
the gene signature for GTF2E1 inhibition as that of FLT1
(i.e., a molecular mediator of preeclampsia symptoms
[5]) inhibition with the altered gene signature mimicking
preeclampsia development.
Our analysis of placental gene expression patterns in
the preeclampsia case-control study also revealed dys-
regulation of the basal transcription pathway and iden-
tified genes coding for the CAK-complex of TFIIH, namely
CDK7, CCNH, and MNAT1, among the largest group of
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of the CAK complex of TFIIH is required for phos-
phorylation of RNA Pol-II [14]. XPD is believed to be
required for stability of the TFIIH and for coordinating
the activity of the CAK complex [12]. Our analyses of
the reactome dataset identified direct interaction between
GTF2E1 and XPD along with other proteins involved in
transcription further pointing towards transcription mech-
anisms as relevant to preeclampsia. Analysis of ENCODE
Chip Seq data confirmed the above findings and suggested
that TTD genes, GTF2E1, FLT1 and selected gene regula-
tors of preeclampsia (such as EGFR and ATF3 [19]) may
be part of the same protein-protein interaction network.
JUNB and JUND, components of transcription factor
AP-1 and proto-oncogenes which interact with specific
target DNA sequences to regulate gene expression, were
identified as regulators of all genes of interest in our net-
work. AP-1 has been implicated in regulation and prolifer-
ation of trophoblasts and has been suggested to play a role
in the pathogenesis of gestational trophoblastic diseases,
which are placental pathologies [38]. TTDN1, which has
been associated with TTD but does not code for a subunit
of TFIIH, was also found to belong to the same gene net-
work regulated by JUNB and JUND, providing possible
insight into its function.
Our overall findings from our studies to date lead us
to propose a mechanism, depicted in Figure 5, involving
impairment of RNA Pol II-mediated transcription in
placenta in association with gestational complications
such as preeclampsia. We propose that impairment of
TFIIH-mediated function in transcription, which may
occur via several mechanisms such as mutations in the
genes coding for the subunits of its core domain (such asFigure 5 Graphical depiction of our proposed mechanism of impairm
leading to preeclampsia. We propose that impairment of TFIIH-mediated
such as mutations in the genes coding for subunits of its core domain (suc
of the subunits of its CAK domain, and/or dysregulation of subunits of oth
is one mechanism leading to preeclampsia. Red arrows depict downregulaTTD-associated mutations in XPD, XPB and TTD-A),
downregulation of the subunits of its CAK domain, and/
or dysregulation of subunits of other transcription factors
with which it interacts such as GTF2E1 of TFIIE, is one
mechanism leading to preeclampsia (Figure 5). Even
though preeclampsia was not noted in pregnancies involv-
ing the three TTD patients with TTD-A mutations in our
previous studies [8,36], we have included TTD-A in our
proposed mechanism, given the risk of other gestational
complications (such as decreased fetal movement) which
may be associated with mutations in this gene.
Our proposed mechanism does not preclude other
mechanisms which may be involved in preeclampsia
development and may not explain all cases of preeclampsia.
Taking advantage of the rich resource of publicly-available
gene expression datasets, we designed a systems biology
approach to select specific and relevant datasets for fo-
cused analyses addressing our study hypothesis. A limi-
tation of this approach is that the secondary data used
in our study were created to test different hypotheses than
the one conceived by us. Thus, some of the datasets may
not have been ideal for our study. For example, even
though we tried to restrict our analyses to datasets which
had biopsied placental tissues believed to be predomin-
antly of fetal-cell origin, we cannot rule out the pres-
ence of mixed maternal and fetal cell-derived histology
in some datasets (such as GSE5999 [22]) causing differ-
ential trophoblast composition.
Critical questions about our proposed mechanism re-
main to be answered and include the stage of placental
development affected by TFIIH and/or TFIIE impairment
potentially leading to preeclampsia. The initial defect
leading to preeclampsia is generally believed to be poorent of TFIIH-mediated function in transcription in placenta
function in transcription, which may occur via several mechanisms
h as TTD-associated mutations in XPD, XPB and TTD-A), downregulation
er transcription factors with which it interacts such as GTF2E1 of TFIIE,
tion. Yellow symbols depict mutations.
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remodeling of the maternal uterine spiral arteries, thereby
compromising blood flow to the placenta causing placental
ischemia-hypoxia and oxidative stress [3-7]. It is plausible
that TFIIH and/or TFIIE impairment in placenta affect
trophoblast proliferation, differentiation and/or migration
creating the early defects which may lead to preeclampsia.
A recent study examining transcriptional changes asso-
ciated with differentiation from villous to extravillous
first-trimester trophoblasts reported significantly higher
expression of certain transcription-related factors such as
JUN, ATF3, and EGFR in villous trophoblasts [39]. These
findings hint at the relevance of these transcription factors
to trophoblast differentiation and are consistent with our
findings. ATF3 and EGFR were implicated as the main
regulators of preeclampsia development in our previous
integrative transcriptome analysis [19]. JUNB and JUND
were highlighted in our current analyses as transcription
regulators of the network involving the TTD genes,
GTF2E1, ATF3 and EGFR.
Another critical question which remains to be resolved
pertains to the effect of hypoxia and oxidative stress
on TFIIH and/or TFIIE function. In our previous study
[19], XPD (ERCC2) was significantly down-regulated
(FDR < 0.01, Fold Change = 1.65) in hypoxic human
trophoblasts (Swan 71 human trophoblast cells under
chemical hypoxia by CoCl2-treatment) in an in vitro
system (GSE31679) [40]. In mouse studies, TTD/XPA
double mutant cells were found to be hypersensitive to
oxidative stress [41]. Recent findings of XPD’s involve-
ment in apoptosis [42], make it theoretically plausible
that TFIIH impairment could contribute to increased
syncytialtrophoblast apoptosis/necrosis caused as the
result of prolonged hypoxia and reoxygenation. The
interrelationship of hypoxia and oxidative stress with
TFIIH and/or TFIIE function remains to be explored in
future focused experiments.
Conclusion
Our investigations suggest an important role for TTD
NER/transcription genes in placenta during gestational
periods critical with respect to preeclampsia develop-
ment and implicate impaired TFIIH-mediated function
in transcription in placenta as a likely mechanism lead-
ing to preeclampsia. Our findings provide etiologic and
mechanistic clues which can eventually be translated
into therapeutic and/or preventive measures against
preeclampsia.
Methods
Raw data from relevant datasets were downloaded from
GEO (http://www.ncbi.nlm.nih.gov/gds/). These included
datasets containing global gene expression patterns of
normal human tissue including placenta (GSE96) [21],time-course placenta from first, second and third trimester
pregnancies (GSE5999) [22], and normal and preeclamptic
placenta from a case-control study of preeclampsia
(GSE10588) [23]. Other relevant datasets downloaded
and analyzed included a human umbilical vein endothelial
cells (HUVEC) transcriptome dataset (GSE27871) [27] cre-
ated using siRNA-mediated knockdown of 400 factors, the
reactome dataset [28], and raw data from the Encyclopedia
of DNA Elements (ENCODE) [29] dataset.
Analysis of NER/transcription gene profiles in normal
human placenta
We conducted comparison of expression of NER/
transcription genes in placenta versus other normal
tissue including skin in GSE96 [21] via ANOVA models
(Method of Moments [43]) using Partek software version
6.6 (Partek Inc., St. Louis, MO, USA). GSE96 contains global
gene expression patterns (normal transcriptome) of 79
diverse human tissues including placenta. Placental biopsies
were collected at term from four Caucasians ages 21-39 [21].
Temporal analysis of NER/transcription genes in placenta in
GSE5999 [22] was done through Pearson correlation ana-
lysis, using time as a variable. GSE5999 contains global gene
expression patterns of basal plate (maternal-fetal interface)
of 36 placentas from 14 to 40 weeks gestation obtained
at the conclusion of normal pregnancies.
Placental gene expression profiles in a preeclampsia
case-control study
The objective for analysis of GSE10588 [23] was to
compare global gene expression profiles in placenta
from normotensive pregnancies (controls) to placentas
from preeclamptic pregnancies (cases). This dataset
was the largest preeclampsia case-control study identi-
fied through GEO (http://www.ncbi.nlm.nih.gov/gds/)
and included patterns of gene expression on tissue bi-
opsies from fetal cell-derived histological subsections
of the placenta as per our selection criteria. This dataset
ascertained cases of severe preeclampsia as defined by the
American College of Obstetricians and Gynecologists [44]
occurring early-onset (i.e., diagnosis <34 weeks gestation)
and matched case (n = 21) and control (n = 21) placentas
based on gestational age.
GSE10588 was previously analyzed with respect to
global differential gene expression patterns. We con-
ducted a novel analysis on this dataset by using the Al-
gorithm for the Reconstruction of Accurate Cellular
Networks (ARACNe) [25] integrated into GeWorkbench
(http://wiki.c2b2.columbia.edu/workbench) in order to
infer transcriptional relationships and identify key gene
regulators. ARACNE is an information-theory based
method developed to reconstruct gene regulatory net-
works in mammalian cellular context using gene expres-
sion profiles [25]. ARACNE calculates Mutual Information
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(edges) between more than two genes (nodes) are found,
ARACNE uses the Data Processing Inequality (DPI) al-
gorithm to remove the weakest interaction. In our ana-
lyses, the threshold for MI was set at p = 10−7 and DPI
was set at 0.15.
Further analysis of GSE10588 involved identifying
protein-protein interaction sub-networks of the sig-
nificant (q < 0.01, Fold Change ≥ 1.3) preeclampsia-
specific gene list through application of Cytoscape
[45] MiMI plugin [46] using the reactome dataset [28],
employing direct-only protein-protein interactions as a
filter. The reactome dataset [28] contains information
on 2975 human proteins and 2907 protein-protein
interactions.Transcriptome analysis of human umbilical vein
endothelial cells
In order to compare the affected gene regulatory net-
works of GTF2E1 and FLT1, we analyzed raw data from
a HUVEC transcriptome dataset (GSE27871) [27] created
using siRNA-mediated knockdown of 400 specific signaling
molecules and transcription factors. Correlation matrix
for the 400 gene knockdown microarrays was created
using Pearson correlation between individual knock-
down datasets; an FDR cutoff of less than 0.05 was used.
Correlation coefficient (R) was used as an input in the
network construction and Edge-Weighted Spring Embedded
layout algorithm was used to create the network. Gene
clusters were identified via ClusterOne Cytoscape plugin
[47] using default settings.Analysis of relevant datasets to identify common
regulatory networks of genes implicated in preeclampsia
The reactome dataset [28] was also used for the identifi-
cation of proteins and protein complexes with first- and
second-degree interactions with GTF2E1.
In order to infer potential common transcriptional
regulatory networks of selected genes and gene regulators
implicated in preeclampsia, analysis of the ENCODE Chip
Seq derived regulatory network data [29] was conducted
in Cytoscape [48]. ENCODE contains genomic binding
information of 119 transcription-related factors in >450
distinct experiments providing regulatory information
crucial for understanding basic principles of human biology
and disease.Endnote
aReferences for most XPD mutations analyzed in
our previous report can be found in Table four of
Cleaver et al. [49].Additional file
Additional file 1: Figure S1. NER/transcription gene expression profiles
in normal human placenta. Panel a. Bar graph depicting expression
(relative fluorescence intensity shown on log2 scale) of three TTD NER/
transcription genes in normal human tissue array including placenta
in GSE 96 [21]. Red bar represents the placenta and green bar represents
the skin. Panel b. Temporal expression patterns of the three TTD NER/
transcription genes in placenta from 14 to 40 weeks gestation in GSE5999
[22]. Circles represent individual placental samples.
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